汇添富国证生物医药ETF(159839)利润分配表
| |
2024-12-31 |
2024-06-30 |
2023-12-31 |
2023-06-30 |
| 收入 |
-131,224,146.15 |
-168,497,820.63 |
-130,015,392.83 |
-151,634,514.75 |
| 利息合计 |
135,472.56 |
123,256.23 |
166,639.80 |
12,370.84 |
| 其中：存款利息收入 |
21,414.74 |
9,198.41 |
26,321.47 |
12,370.84 |
| 债券利息收入 |
- |
- |
- |
- |
| 资产支持证券利息收入 |
- |
- |
- |
- |
| 买入返售金融资产收入 |
- |
- |
- |
- |
| 投资收益合计 |
-122,958,285.74 |
-55,575,794.62 |
-100,133,188.29 |
-25,936,054.86 |
| 其中：股票投资收益 |
-130,296,684.91 |
-60,743,210.31 |
-105,787,796.49 |
-30,460,942.94 |
| 基金投资收益 |
- |
- |
- |
- |
| 债券投资收益 |
- |
- |
- |
- |
| 资产支持证券投资收益 |
- |
- |
- |
- |
| 衍生工具收益 |
- |
- |
- |
- |
| 股利收益 |
7,338,399.17 |
5,167,415.69 |
5,654,608.20 |
4,524,888.08 |
| 基金分红收益收益 |
- |
- |
- |
- |
| 公允价值变动收益 |
-9,708,804.68 |
-113,586,651.02 |
-31,208,620.78 |
-126,325,858.93 |
| 其他收入 |
1,307,471.71 |
541,368.78 |
1,159,776.44 |
615,028.20 |
| 费用 |
3,148,022.18 |
1,570,015.54 |
3,716,514.32 |
1,736,711.10 |
| 管理人报酬 |
2,466,574.17 |
1,227,886.58 |
2,951,544.59 |
1,375,443.71 |
| 基金托管费 |
493,314.83 |
245,577.29 |
590,308.98 |
275,088.74 |
| 销售服务费 |
- |
- |
- |
- |
| 交易费用 |
- |
- |
- |
- |
| 利息支出 |
- |
- |
- |
- |
| 其中：卖出回购金融资产支出 |
- |
- |
- |
- |
| 其他费用 |
187,722.51 |
96,141.00 |
174,155.41 |
86,178.65 |
| 利润总额 |
-134,372,168.33 |
-170,067,836.17 |
-133,731,907.15 |
-153,371,225.85 |
微信公众号
证券之星APP
基本资料
